The biggest approval of the third quarter was not a new drug, but an oral version of Novo Nordisk’s semaglutide, branded Rybelsus, which has a consensus sales forecast of $3.3 billion in 2024. Rybelsus is entering a  crowded field with over six other glucagonlike peptide 1 receptor agonists already approved, including Novo’s once- weekly injectable version of semaglutide, Ozempic…

Para acessar a publicação na íntegra clique aqui

Fonte:816 | NOVEMBER 2019 | volume 18 www.nature.com/nrd